KR910006291A - 헤테로시클릭 화합물 - Google Patents
헤테로시클릭 화합물 Download PDFInfo
- Publication number
- KR910006291A KR910006291A KR1019900014226A KR900014226A KR910006291A KR 910006291 A KR910006291 A KR 910006291A KR 1019900014226 A KR1019900014226 A KR 1019900014226A KR 900014226 A KR900014226 A KR 900014226A KR 910006291 A KR910006291 A KR 910006291A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- hydrogen atom
- atom
- metabolically
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 125000006239 protecting group Chemical group 0.000 claims 7
- -1 salts thereof Chemical class 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 4
- 125000000468 ketone group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 238000007363 ring formation reaction Methods 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000006356 dehydrogenation reaction Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 하기 일반식(Ⅰ)의 화합물, 그의 내염을 포함한 염, 대사적으로 변성가능한 에스테르 및 용매화합물.식중, R1은 수소원자 또는 히드록실 보호기를 나타내고, R2는 수소원자, 카르복실 보호기를 나타내고, R3은 수소원자, 히드록실기, 히드록시메틸기 또는 C1-3알킬기를 나타내거나, 또는 기XR1〔여기에서, X는 산소원자 또는 기S(O)n (여기서 n는 0이거나 1 또는 2의 정수이다)를 나타내고 R4는 C1-5알킬, C3-7시클로알킬 또는 페닐기를 나타내거나, 또는 X가 산소 또는 황원자인 경우 R4는 기 AlkNR5R6(여기서 Alk는 C2-6선형 또는 분지형 알킬렌쇄를 나타내고, R5및 R6는 각각 독립적으로 수소원자 또는 C1-4알킬기를 나타내거나, 또는 R5는 포르밀기, 아세틸기 또는 이미노메틸기를 나타내고, R6는 수소원자를 나타내거나 또는 R5및 R6는 이들의 결합된 질소원자와 함께 피롤리디노 또는 피페리디노 고리를 형성한다)를 나타낼 수 있다〕를 나타내거나, 또는 R3는 기(CH2) mNR7R8(여기에서, m은 0 또는 1이고, R7및 R8는 각각 독립적으로 수소원자 또는 C1-4알킬기를 나타내거나, 또는 R7은 포르밀기, 아세틸기 또는 이미노메틸기를 나타내고, R8는 수소원자를 나타낸다)을 나타내거나, 또는 R3은 이것이 결합된 탄소원자와 함께 케토기 또는 그의 케탈 유도체를 나타낸다.
- 제1항에 있어서, 상기 R1및 R2가 수소원자를 나타내는 화합물 및 그의 내염을 포함한 생리학상 허용되는 염, 대사적으로 변성가능한 에스테르 및 용매 화합물.
- 제2항에 있어서, 상기 R3가 수소원자 또는 아미노, 아미노메틸, 메틸아미노, 히드록시, 히드록시메틸, 메틸, 메톡시, 에톡시, 이소프로폭시, 시클로펜톡시, 아미노에톡시, 메틸티오, 페닐티오 또는 메틸술피닐기를 나타내거나 또는 이것이 결합된 탄소원자와 함께 케토 또는 디메틸케탈기를 형성하는 것인 화합물.
- 제1항 내지 3항중 어느 한 항에 있어서, 8위치의 탄소원자가 β-배위인 화합물.
- 하기 일반식(Ⅰb)의 화합물 및 이들의 생리학상 허용되는 염, 대사적으로 변성가능한 에스테르 및 용매 화합물.(식중, R3은 아미노, 아미노메틸, 메틸아미노, 히드록시, 히드록시메틸, 메톡시, 에톡시, 이소프로폭시, 아미노에톡시, 메틸티오, 메틸술피닐 또는 페닐티오기를 나타낸다).
- (4S,8S,9R,10S,12R)-4-메톡시-10-(1-히드록시에틸)-11-옥소-1-아자트리시클로〔7,2,0,0〕운데스-2-엔-2-카르복실산 및 그의 생리학상 허용되는 염, 대사적으로 변성 가능한 에스테르 및 용매화합물.
- 다음의 화합물, (4S,8S,9R,10S,12R)-4-메틸티오-10-(1-히드록시에틸)-11-옥소-1-아자트리시클로〔7,2,0,〕운데스-2-엔-2-카르복실산, (4S,8S,9R,10S,12R)-4-메틸술피닐-10-(1-히드록시에틸)-11-옥소-1-아자트리시클로〔7,2,0,〕운데스-2-엔-2-카르복실산, (4S,8S,9R,10S,12R)-4-아미노-10-(1-히드록시에틸)-11-옥소-1-아자트리시클로〔7,2,0,〕운데스-2-엔-2-카르복실산 및 그의 생리학상 허용되는 염, 대사적으로 변성 가능한 에스테르 및 용매 화합물.
- (ⅰ) 하기 일반식(Ⅱ)의 화합물의 환화 단계,(식중, R1a는 히드록실 보호기이고, R2a는 카르복실 보호기이며 R3a는 R3에 대해 정의된 바와 같거나 또는 이것으로 전환 가능한 기이고, Y는 산소원자 또는 포스핀기이다).(ⅱ) 화합물(Ⅰ) 〔여기에서, R2는 카르복실 보호기이고, R3은 기SR4(여기서 R4는 제1항에서 정의한 바와 같다)이다 〕의 산화에 의해 화합물(Ⅰ) (여기에서, R3은 기SOR4이다)을 생성하는 단계,(식중, R1, R2및 R3은 상기 제1항에서 정의한 바와 같다) (ⅲ) 화합물(Ⅰ) (여기에서 R2는 카르복실 보호기이고, R3은 이것이 결합된 탄소원자와 함께 케탈기를 나타낸다)의 가수분해에 의해 화합물(Ⅰ) (여기에서 R3은 이것이 결합된 탄소원자와 함께 케토기를 나타낸다)을 생성하는 단계, (ⅳ) 화합물(Ⅰ) (여기에서, R2는 카르복실 보호기이고, R3은 이것이 결합된 탄소원자와 함께 케토기를 나타낸다)의 환원에 의해 화합물(Ⅰ) (여기에서, R3은 히드록실기이다)을 생성하는 단계, (ⅴ) 화합물(Ⅰ) (여기에서, R1은 히드록실 보호기이고, R2는 카르복실 보호기이고, R3은 히드록실기이다)의 0-알킬화에 의해 화합물(Ⅰ) (여기에서, R3은 알콕시기이다)을 생성하는 단계 중 어느 한 단계에 있어서, 필요할 경우 생성된 화합물들을, 그들이 입체 이성질체로 분리하기 전후에, a)목적하는 기R3로의 기R3a의 전환, b)한 개 이상의 보호기의 제거,또는 c)R2가 수소원자이거나 또는 카르복실 보호기인 화합물의 대응하는 염, 대사적으로 변형 가능한 에스테르 또는 용매 혼합물로의 전환시키는 반응 중 한 개 이상을 행하는 것으로 되는 제1항에 따른 화합물의 제조방법.
- 제8항에 있어서 일반식(Ⅱ)의 화합물 (여기에서, Y는 산소원자이다)의 환화를 유기 아인산염의 존재하에서 가열에 의해 행하는 것인 방법.
- 인간 및 동물 개체에 있어서 전신 또는 국소적 세균 감염의 치료 또는 예방에 사용하기 위한 제2항 내지 7항중 어느 한 항에 따르는 화합물.
- 인체 및 동물체에 있어서 전신 또는 국소적 세균 감염의 예방 치료용의 치료제를 제조함에 있어서 제2항 내지 7항중 어느 한 항에 청구된 화합물의 용도.
- 제2항 내지 7항중 어느 한 항에 청구된 화합물을 한 개 이상의 생리학상 허용되는 담체 또는 부형제와 혼합시킨 것으로 되는 제약 조성물.
- 제2항 내지 7항중 어느 한 항에서 청구된 바와 같은 화합물 유효량을 인체 또는 비인체에 투여하는 것으로 되는 세균 감염증을 퇴치하기 위한 치료 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT89203376 | 1989-09-08 | ||
| GB898920337A GB8920337D0 (en) | 1989-09-08 | 1989-09-08 | Heterocyclic compounds |
| GB909015484A GB9015484D0 (en) | 1990-07-13 | 1990-07-13 | Heterocyclic compounds |
| IT90154840 | 1990-07-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR910006291A true KR910006291A (ko) | 1991-04-29 |
| KR100188175B1 KR100188175B1 (ko) | 1999-06-01 |
Family
ID=26295887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019900014226A KR100188175B1 (ko) | 1989-09-08 | 1990-09-07 | 헤테로시클릭 화합물 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US5407931A (ko) |
| EP (2) | EP0416952B1 (ko) |
| JP (2) | JP3035325B2 (ko) |
| KR (1) | KR100188175B1 (ko) |
| AT (2) | ATE150022T1 (ko) |
| AU (1) | AU632163B2 (ko) |
| CA (1) | CA2024880C (ko) |
| CZ (1) | CZ435990A3 (ko) |
| DD (1) | DD298102A5 (ko) |
| DE (2) | DE69030147T2 (ko) |
| DK (1) | DK0416953T3 (ko) |
| ES (2) | ES2095860T3 (ko) |
| FI (1) | FI93450C (ko) |
| GR (1) | GR3023647T3 (ko) |
| HR (1) | HRP940559B1 (ko) |
| HU (1) | HU218222B (ko) |
| IE (1) | IE903257A1 (ko) |
| IL (1) | IL95609A (ko) |
| MY (1) | MY106980A (ko) |
| NO (1) | NO175479C (ko) |
| NZ (1) | NZ235223A (ko) |
| PL (1) | PL166197B1 (ko) |
| PT (1) | PT95247B (ko) |
| RU (1) | RU2054006C1 (ko) |
| SG (1) | SG73399A1 (ko) |
| SI (1) | SI9011699A (ko) |
| SK (1) | SK435990A3 (ko) |
| YU (1) | YU48073B (ko) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU636913B2 (en) * | 1989-10-11 | 1993-05-13 | Takeda Chemical Industries Ltd. | Tricyclic carbapenem compounds |
| GB9015485D0 (en) * | 1990-07-13 | 1990-08-29 | Glaxo Spa | Heterocyclic derivatives |
| IL99248A (en) * | 1990-08-21 | 1996-01-31 | Glaxo Spa | Acid esters 01-) 1-Hydroxyethyl (-11-oxo-1-azatricycloundec-2-n-2-carboxylic acid, their preparation and pharmaceutical preparations |
| GB9104769D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
| GB9104832D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
| GB9104833D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
| GB9104838D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
| AP198A (en) * | 1991-03-07 | 1992-06-30 | Glaxo Spa | Heterocyclic compounds. |
| EP0507313A1 (en) * | 1991-04-05 | 1992-10-07 | Takeda Chemical Industries, Ltd. | Polycyclic carbapenem compounds, their production and use |
| TW198035B (ko) * | 1991-05-29 | 1993-01-11 | Hoechst Ag | |
| GB9218240D0 (en) * | 1992-08-27 | 1992-10-14 | Glaxo Spa | Heterocyclic compounds |
| GB9218781D0 (en) * | 1992-09-04 | 1992-10-21 | Glaxo Spa | Heterocyclic derivatives |
| GB9305805D0 (en) * | 1993-03-20 | 1993-05-05 | Glaxo Spa | Chemical process |
| GB9305806D0 (en) * | 1993-03-20 | 1993-05-05 | Glaxo Spa | Chemical compounds |
| GB9305813D0 (en) * | 1993-03-20 | 1993-05-05 | Glaxo Spa | Chemical process |
| GB9305853D0 (en) * | 1993-03-20 | 1993-05-05 | Glaxo Spa | Chemical compounds |
| US5849907A (en) * | 1993-03-20 | 1998-12-15 | Glaxo Wellcome Spa | Chemical process |
| US5374630A (en) * | 1993-06-10 | 1994-12-20 | Merck & Co., Inc. | Bridged carbapenem antibacterial compounds |
| US5372993A (en) * | 1993-06-10 | 1994-12-13 | Merck & Co., Inc. | Bridged carbapenem compounds, compositions containing such compounds and methods of use |
| US5401735A (en) * | 1993-08-02 | 1995-03-28 | Merck & Co., Inc. | Bridged biphenyl carbapenem antibacterial compounds |
| US5384317A (en) * | 1993-08-02 | 1995-01-24 | Merck & Co., Inc. | Bridged biphenyl carbapenem compounds, compositions containing such compounds and methods of use |
| GB9323137D0 (en) * | 1993-11-10 | 1994-01-05 | Glaxo Spa | Chemical compounds |
| GB9403729D0 (en) * | 1994-02-26 | 1994-04-13 | Glaxo Spa | Amine derivatives |
| GB9406074D0 (en) * | 1994-03-26 | 1994-05-18 | Glaxo Spa | Chemical process |
| GB2287709A (en) * | 1994-03-26 | 1995-09-27 | Glaxo Spa | Silylated azetidinone intermediates |
| US5698547A (en) * | 1994-04-01 | 1997-12-16 | Microcide Pharmaceuticals, Inc. | Cephalosporin antibiotics |
| US5688786A (en) * | 1994-04-01 | 1997-11-18 | Microcide Pharmaceuticals, Inc. | β-lactam antibiotics |
| GB9516118D0 (en) * | 1995-08-05 | 1995-10-04 | Glaxo Spa | Chemical process |
| GB9623684D0 (en) * | 1996-11-14 | 1997-01-08 | Glaxo Wellcome Spa | Chemical compounds |
| US6531466B2 (en) | 1996-11-14 | 2003-03-11 | Glaxosmithkline Spa | Tricyclic carbapenem compounds |
| JPH10168057A (ja) * | 1996-12-12 | 1998-06-23 | Takasago Internatl Corp | シクロヘキシルアゼチジノン誘導体の製造法 |
| WO1998034937A1 (fr) * | 1997-02-10 | 1998-08-13 | Sankyo Company, Limited | Composes heterocycliques tricycliques |
| US5994343A (en) * | 1997-10-02 | 1999-11-30 | Merck & Co., Inc. | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment |
| CA2306632A1 (en) * | 1997-10-23 | 1999-04-29 | Merck & Co., Inc. | Carbapenem antibacterial compounds, compositions and methods of treatment |
| US6207823B1 (en) * | 1997-10-23 | 2001-03-27 | Merck & Co., Inc. | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment |
| US6271222B1 (en) | 1998-05-28 | 2001-08-07 | Merck & Co., Inc. | Penem antibacterial compounds, compositions and methods of treatment |
| CN101367817B (zh) * | 2007-06-26 | 2011-01-12 | 山东轩竹医药科技有限公司 | 含有环己烯酮甲酰氨基的碳青霉烯化合物 |
| EP2085084A1 (en) * | 2008-01-29 | 2009-08-05 | LEK Pharmaceuticals D.D. | Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics |
| EP2135871A1 (en) * | 2008-06-18 | 2009-12-23 | LEK Pharmaceuticals D.D. | New trinem antibiotics and inhibitors of beta-lactamases |
| AU2018265192B2 (en) | 2017-05-08 | 2021-06-17 | Glaxosmithkline Intellectual Property Development Limited | Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection |
| KR102471353B1 (ko) * | 2020-07-03 | 2022-11-28 | 한국공학대학교산학협력단 | 바이메탈을 이용한 복원 기능을 포함하는 퓨즈 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260627A (en) * | 1978-10-24 | 1981-04-07 | Merck & Co., Inc. | 1-, 6- And 2-substituted-1-carba-2-penem-3-carboxylic acids |
| US4600713A (en) * | 1979-12-03 | 1986-07-15 | Merck & Co., Inc. | 1-, 6- and 2-substituted-1-carba-2-penem-3-carboxylic acids |
| US4374848A (en) * | 1981-09-14 | 1983-02-22 | Merck & Co., Inc. | 6-(1-Hydroxyethyl)cyclonocardicin |
| US4374849A (en) * | 1981-09-14 | 1983-02-22 | Merck & Co., Inc. | 6-Amidocyclonocardicins |
| JPS61236785A (ja) * | 1985-04-15 | 1986-10-22 | Sankyo Co Ltd | アゼチジノン誘導体 |
| GB8607921D0 (en) | 1986-04-01 | 1986-05-08 | Fujisawa Pharmaceutical Co | 3,4-disubstituted-2-azetidinone derivatives |
| AU636913B2 (en) * | 1989-10-11 | 1993-05-13 | Takeda Chemical Industries Ltd. | Tricyclic carbapenem compounds |
-
1990
- 1990-09-04 CZ CS904359A patent/CZ435990A3/cs not_active IP Right Cessation
- 1990-09-06 SI SI9011699A patent/SI9011699A/sl unknown
- 1990-09-06 DD DD90343863A patent/DD298102A5/de not_active IP Right Cessation
- 1990-09-06 YU YU169990A patent/YU48073B/sh unknown
- 1990-09-07 IE IE325790A patent/IE903257A1/en not_active IP Right Cessation
- 1990-09-07 IL IL9560990A patent/IL95609A/en not_active IP Right Cessation
- 1990-09-07 ES ES90309847T patent/ES2095860T3/es not_active Expired - Lifetime
- 1990-09-07 DE DE69030147T patent/DE69030147T2/de not_active Expired - Fee Related
- 1990-09-07 DE DE69029627T patent/DE69029627T2/de not_active Expired - Fee Related
- 1990-09-07 JP JP2235975A patent/JP3035325B2/ja not_active Expired - Fee Related
- 1990-09-07 SG SG1996006269A patent/SG73399A1/en unknown
- 1990-09-07 FI FI904423A patent/FI93450C/fi not_active IP Right Cessation
- 1990-09-07 CA CA002024880A patent/CA2024880C/en not_active Expired - Fee Related
- 1990-09-07 KR KR1019900014226A patent/KR100188175B1/ko not_active IP Right Cessation
- 1990-09-07 ES ES90309848T patent/ES2100872T3/es not_active Expired - Lifetime
- 1990-09-07 EP EP90309847A patent/EP0416952B1/en not_active Expired - Lifetime
- 1990-09-07 US US07/578,948 patent/US5407931A/en not_active Expired - Fee Related
- 1990-09-07 AT AT90309848T patent/ATE150022T1/de not_active IP Right Cessation
- 1990-09-07 NZ NZ235223A patent/NZ235223A/xx unknown
- 1990-09-07 EP EP90309848A patent/EP0416953B1/en not_active Expired - Lifetime
- 1990-09-07 US US07/578,949 patent/US5138048A/en not_active Expired - Fee Related
- 1990-09-07 PT PT95247A patent/PT95247B/pt not_active IP Right Cessation
- 1990-09-07 AT AT90309847T patent/ATE147394T1/de active
- 1990-09-07 JP JP2235976A patent/JP3018442B2/ja not_active Expired - Lifetime
- 1990-09-07 AU AU62265/90A patent/AU632163B2/en not_active Ceased
- 1990-09-07 SK SK4359-90A patent/SK435990A3/sk unknown
- 1990-09-07 HU HU826/90A patent/HU218222B/hu not_active IP Right Cessation
- 1990-09-07 DK DK90309848.1T patent/DK0416953T3/da active
- 1990-09-07 PL PL90286796A patent/PL166197B1/pl unknown
- 1990-09-07 MY MYPI90001540A patent/MY106980A/en unknown
- 1990-09-07 NO NO903914A patent/NO175479C/no unknown
-
1992
- 1992-06-04 RU SU5011726/04A patent/RU2054006C1/ru not_active IP Right Cessation
-
1994
- 1994-09-16 HR HRP-1699/90A patent/HRP940559B1/xx not_active IP Right Cessation
-
1997
- 1997-05-09 GR GR970401017T patent/GR3023647T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910006291A (ko) | 헤테로시클릭 화합물 | |
| DE3775882D1 (de) | Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeuren ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen. | |
| DK0802911T3 (da) | Hydrofobe taxanderivater | |
| GB2331015A (en) | Therapeutic methods and compositions involving isoflavones | |
| BR0013949A (pt) | Prodroga de taxano, composição farmacêutica, e, método de tratamento de um paciente mamìfero | |
| KR940014374A (ko) | 6,7-변형 패클리탁셀 | |
| ATE243702T1 (de) | Verfahren zur herstellung von ascorbinsäurederivaten | |
| ATE132145T1 (de) | Verfahren zur herstellung von bacchatin iii und von desacetyl-10-bacchatin iii derivate | |
| KR910016931A (ko) | 과콜레스테린혈증 치료제 | |
| ATE1192T1 (de) | Verfahren zur herstellung von beta-lactam-derivaten, die so erhaltenen neuen derivate sowie diese derivate enthaltende pharmazeutische zusammensetzungen. | |
| ATE143601T1 (de) | Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose | |
| KR930016436A (ko) | 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물 | |
| KR910014395A (ko) | 신규 화합물 | |
| ATE193286T1 (de) | 10- deacetylbaccatin iii und 10- deacetyl 14 beta hydroxybaccatin iii derivaten, verfahren zu deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen | |
| KR880001677A (ko) | β-락탐 화합물, 그의 제조 방법, 이를 함유하는 세균 감염성 질병 치료용 약제 및 그의 합성을 위한 중간체 | |
| KR910011881A (ko) | 신규 화합물 | |
| KR920702361A (ko) | 10(1-히드록시에틸)-11-옥소-1-아자트리시클로[7.2.0.0.3.8]운데스-2-엔-2-카르복실산 에스테르 및 그의 제조 방법 | |
| KR880000432A (ko) | 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체 | |
| ATE149165T1 (de) | Stickstoff enthaltende bizyklische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| DE60043293D1 (de) | VAKUOLAR-TYP (H+)-ATPase-HEMMENDE VERBINDUNGEN, ZUSAMMENSETZUNGEN UND DEREN VERWENDUNGEN | |
| ATE121405T1 (de) | Oxazolopyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| ATE166060T1 (de) | Neue (estradiol-derivat)-chlorambucil-konjugate, verfahren zu ihrer herstellung und pharmazeutische präparate | |
| CA2385301A1 (en) | Peeling composition | |
| ATE120647T1 (de) | Superoxid-dismutase-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel. | |
| ATE66920T1 (de) | Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| FPAY | Annual fee payment |
Payment date: 20011226 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |